Pub Date : 2025-11-13DOI: 10.1038/s44220-025-00536-x
John Jamir Benzon R. Aruta
In this Comment, Aruta explores how climate change and digital mental health intersect. The Comment maps four domains of convergence with global relevance and calls for an integrated agenda for research, policy and practice.
{"title":"Low-carbon, high-justice care: making digital mental health climate ready","authors":"John Jamir Benzon R. Aruta","doi":"10.1038/s44220-025-00536-x","DOIUrl":"10.1038/s44220-025-00536-x","url":null,"abstract":"In this Comment, Aruta explores how climate change and digital mental health intersect. The Comment maps four domains of convergence with global relevance and calls for an integrated agenda for research, policy and practice.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 12","pages":"1457-1458"},"PeriodicalIF":8.7,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-06DOI: 10.1038/s44220-025-00549-6
Perinatal mental health conditions remain under-recognized and undertreated, despite their effect on maternal morbidity and mortality and infant and child development. There is an urgent need for increased awareness, challenging stigma, screening and intervention during the perinatal period to improve outcomes for mothers and children.
{"title":"Expecting better: improving perinatal mental health","authors":"","doi":"10.1038/s44220-025-00549-6","DOIUrl":"10.1038/s44220-025-00549-6","url":null,"abstract":"Perinatal mental health conditions remain under-recognized and undertreated, despite their effect on maternal morbidity and mortality and infant and child development. There is an urgent need for increased awareness, challenging stigma, screening and intervention during the perinatal period to improve outcomes for mothers and children.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 11","pages":"1291-1292"},"PeriodicalIF":8.7,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s44220-025-00549-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-06DOI: 10.1038/s44220-025-00542-z
Ana Donnelly
{"title":"Bound by love and diagnosis","authors":"Ana Donnelly","doi":"10.1038/s44220-025-00542-z","DOIUrl":"10.1038/s44220-025-00542-z","url":null,"abstract":"","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 11","pages":"1301-1301"},"PeriodicalIF":8.7,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-06DOI: 10.1038/s44220-025-00529-w
Michael M. Halassa
Xanomeline/trospium (Cobenfy) was recently approved by the US Food and Drug Administration for the treatment of adults with schizophrenia. Despite promising findings in placebo-controlled trials, there is limited understanding of its real-world use. Here we perform a post-hoc analysis of medical records following Cobenfy add-on administration in an inpatient population. In an initial cohort of 24 patients, ~40% experienced positive responses. To identify predictive clinical features, we used a combination of hierarchical clustering and linear discriminant analysis, which showed that negative symptoms and stimulant use were the largest predictors of a positive response, while the presence of intellectual delay was negatively predictive. This pattern was independently replicated in 25 patients. Overall, this work supports the notion of biologically distinct psychosis subgroups and invites further research into the underlying biological substrates. In this study, a post-hoc analysis of medical records for individuals being treated with Cobenfy investigates real-world effectiveness, identifying predictors of response and suggesting the existence of biologically distinct psychosis subgroups.
{"title":"Preliminary real-world predictors of response to muscarinic targeting in psychosis","authors":"Michael M. Halassa","doi":"10.1038/s44220-025-00529-w","DOIUrl":"10.1038/s44220-025-00529-w","url":null,"abstract":"Xanomeline/trospium (Cobenfy) was recently approved by the US Food and Drug Administration for the treatment of adults with schizophrenia. Despite promising findings in placebo-controlled trials, there is limited understanding of its real-world use. Here we perform a post-hoc analysis of medical records following Cobenfy add-on administration in an inpatient population. In an initial cohort of 24 patients, ~40% experienced positive responses. To identify predictive clinical features, we used a combination of hierarchical clustering and linear discriminant analysis, which showed that negative symptoms and stimulant use were the largest predictors of a positive response, while the presence of intellectual delay was negatively predictive. This pattern was independently replicated in 25 patients. Overall, this work supports the notion of biologically distinct psychosis subgroups and invites further research into the underlying biological substrates. In this study, a post-hoc analysis of medical records for individuals being treated with Cobenfy investigates real-world effectiveness, identifying predictors of response and suggesting the existence of biologically distinct psychosis subgroups.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 12","pages":"1512-1518"},"PeriodicalIF":8.7,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-06DOI: 10.1038/s44220-025-00540-1
Natalia Gass
{"title":"Tuning in to your heart","authors":"Natalia Gass","doi":"10.1038/s44220-025-00540-1","DOIUrl":"10.1038/s44220-025-00540-1","url":null,"abstract":"","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 11","pages":"1300-1300"},"PeriodicalIF":8.7,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-05DOI: 10.1038/s44220-025-00520-5
Karen Wetherall, Seonaid Cleare, Nadia Belkadi, Marianne E. Etherson, Krystyna J. Loney, Susan Mathew, James Munro, Ellen Townsend, Matthew K. Nock, Eamonn Ferguson, Rory C. O’Connor
The biological underpinnings of self-harm in young people are unclear. Self-harm often serves to regulate emotions, and electrodermal activity (EDA) is a well-established biomarker of emotional arousal, which is physiologically related to emotion regulation. A quasi-experimental case control study using predefined groups was conducted. Three groups of young people (16–25 years; n = 180) with different self-harm histories were recruited: no self-harm history (n = 62), self-harm ideation last year with no enaction (n = 51) and self-harm enaction last year (n = 67). EDA was measured during three tasks: an auditory tones habituation task, a psychosocial stress task and an emotional images task. Those in the self-harm enaction group elicited a heightened EDA response (hyperreactivity) across two tasks, specifically a slower habituation rate to auditory tones and higher EDA during the psychosocial stress task compared to other groups. High levels of non-response during the emotional images task limited analyses. These findings expand our understanding of the biomarkers for self-harm, specifically emotional arousal in young people who self-harm. Specifically, they suggest that those with a history of self-harm exhibit a heightened electrodermal response to both stressful and non-stressful stimuli compared to those who have no history of self-harm and those who have only thought about self-harm. Young individuals with a history of self-harm exhibit heightened electrodermal activity in response to neutral and stress-related stimuli, extending our understanding of the biophysiological factors for self-harm vulnerability.
{"title":"Emotion processing and electrodermal activity in young people who self-harm","authors":"Karen Wetherall, Seonaid Cleare, Nadia Belkadi, Marianne E. Etherson, Krystyna J. Loney, Susan Mathew, James Munro, Ellen Townsend, Matthew K. Nock, Eamonn Ferguson, Rory C. O’Connor","doi":"10.1038/s44220-025-00520-5","DOIUrl":"10.1038/s44220-025-00520-5","url":null,"abstract":"The biological underpinnings of self-harm in young people are unclear. Self-harm often serves to regulate emotions, and electrodermal activity (EDA) is a well-established biomarker of emotional arousal, which is physiologically related to emotion regulation. A quasi-experimental case control study using predefined groups was conducted. Three groups of young people (16–25 years; n = 180) with different self-harm histories were recruited: no self-harm history (n = 62), self-harm ideation last year with no enaction (n = 51) and self-harm enaction last year (n = 67). EDA was measured during three tasks: an auditory tones habituation task, a psychosocial stress task and an emotional images task. Those in the self-harm enaction group elicited a heightened EDA response (hyperreactivity) across two tasks, specifically a slower habituation rate to auditory tones and higher EDA during the psychosocial stress task compared to other groups. High levels of non-response during the emotional images task limited analyses. These findings expand our understanding of the biomarkers for self-harm, specifically emotional arousal in young people who self-harm. Specifically, they suggest that those with a history of self-harm exhibit a heightened electrodermal response to both stressful and non-stressful stimuli compared to those who have no history of self-harm and those who have only thought about self-harm. Young individuals with a history of self-harm exhibit heightened electrodermal activity in response to neutral and stress-related stimuli, extending our understanding of the biophysiological factors for self-harm vulnerability.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 11","pages":"1374-1383"},"PeriodicalIF":8.7,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s44220-025-00520-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-03DOI: 10.1038/s44220-025-00535-y
Yiran Li, Yiling Zhou, Melissa Vos, Martje Bos, Olivier Steen, Naomi R. Wray, Catharina A. Hartman, Harold Snieder
Neurodevelopmental conditions such as attention-deficit/hyperactivity disorder (ADHD) and autism co-occur with cardiometabolic conditions. However, little is known about the mechanisms underlying this co-occurrence. In this nationwide three-generation study using population-based registers in the Netherlands (n = 15 million), we assessed the familial (co-)aggregation of ADHD, autism and cardiometabolic conditions, and estimated their heritabilities and genetic correlations. ADHD, autism and cardiometabolic conditions showed aggregation and co-aggregation within families and between spouses. Estimated heritabilities of ADHD and autism were moderate (both h2 = 0.5), while those of cardiometabolic conditions ranged from low to moderate (h2 = 0.1–0.4). Genetic correlations between neurodevelopmental and cardiometabolic conditions were modest (rg = –0.02–0.20). Together, these results suggest a partly shared familial liability for neurodevelopmental and cardiometabolic conditions, and environmental factors likely play a more important role in the co-occurrence of neurodevelopmental and cardiometabolic conditions than genetics. These new insights can advance research toward specific etiological mechanisms and inform preventive strategies. Li et al. conducted a nationwide, three-generation study in the Netherlands (n = 15 million) to investigate familial associations between ADHD, autism and cardiometabolic conditions using population-based registers.
{"title":"Familial co-aggregation and shared heritability between neurodevelopmental problems and cardiometabolic conditions","authors":"Yiran Li, Yiling Zhou, Melissa Vos, Martje Bos, Olivier Steen, Naomi R. Wray, Catharina A. Hartman, Harold Snieder","doi":"10.1038/s44220-025-00535-y","DOIUrl":"10.1038/s44220-025-00535-y","url":null,"abstract":"Neurodevelopmental conditions such as attention-deficit/hyperactivity disorder (ADHD) and autism co-occur with cardiometabolic conditions. However, little is known about the mechanisms underlying this co-occurrence. In this nationwide three-generation study using population-based registers in the Netherlands (n = 15 million), we assessed the familial (co-)aggregation of ADHD, autism and cardiometabolic conditions, and estimated their heritabilities and genetic correlations. ADHD, autism and cardiometabolic conditions showed aggregation and co-aggregation within families and between spouses. Estimated heritabilities of ADHD and autism were moderate (both h2 = 0.5), while those of cardiometabolic conditions ranged from low to moderate (h2 = 0.1–0.4). Genetic correlations between neurodevelopmental and cardiometabolic conditions were modest (rg = –0.02–0.20). Together, these results suggest a partly shared familial liability for neurodevelopmental and cardiometabolic conditions, and environmental factors likely play a more important role in the co-occurrence of neurodevelopmental and cardiometabolic conditions than genetics. These new insights can advance research toward specific etiological mechanisms and inform preventive strategies. Li et al. conducted a nationwide, three-generation study in the Netherlands (n = 15 million) to investigate familial associations between ADHD, autism and cardiometabolic conditions using population-based registers.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 12","pages":"1545-1554"},"PeriodicalIF":8.7,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-03DOI: 10.1038/s44220-025-00531-2
Franziska Weinmar, Emma Fransson, Birgit Derntl, Alkistis Skalkidou
Perinatal depression (PeriND) has serious consequences for mothers and children, yet early detection is challenging. Emotion regulation (ER) is increasingly recognized as a key factor for maternal mental health; however, associations with depressive symptoms during the perinatal period remain insufficiently understood. In this prospective, population-based Swedish cohort study (N = 623), we examined whether ER difficulties in the second trimester, assessed via the Difficulties in Emotion Regulation Scale-16 (DERS-16) were associated with depressive symptoms across seven perinatal time points (24–34 and 36–42 weeks antenatal; 1–4, 6–13, 14–23, 24–35 and 36–42 weeks postnatal) as measured by the Edinburgh Postnatal Depression Scale. Higher ER difficulties were significantly associated with elevated depressive symptoms during pregnancy to 14–23 weeks postnatal, independent of confounders. ER difficulties also differed between PeriND symptom trajectories, with higher scores in early and late postnatal-onset groups. These findings highlight ER assessed in the second trimester as a potential vulnerability marker for PeriND, with the DERS-16 offering promise for early risk detection. Targeting ER may provide a promising strategy for mitigating perinatal mental health risks. Weinmar et al. examined the link between emotion regulation and perinatal depression symptoms in a Swedish population-based cohort.
{"title":"Emotion regulation is robustly associated with perinatal depressive symptoms in a Swedish national cohort","authors":"Franziska Weinmar, Emma Fransson, Birgit Derntl, Alkistis Skalkidou","doi":"10.1038/s44220-025-00531-2","DOIUrl":"10.1038/s44220-025-00531-2","url":null,"abstract":"Perinatal depression (PeriND) has serious consequences for mothers and children, yet early detection is challenging. Emotion regulation (ER) is increasingly recognized as a key factor for maternal mental health; however, associations with depressive symptoms during the perinatal period remain insufficiently understood. In this prospective, population-based Swedish cohort study (N = 623), we examined whether ER difficulties in the second trimester, assessed via the Difficulties in Emotion Regulation Scale-16 (DERS-16) were associated with depressive symptoms across seven perinatal time points (24–34 and 36–42 weeks antenatal; 1–4, 6–13, 14–23, 24–35 and 36–42 weeks postnatal) as measured by the Edinburgh Postnatal Depression Scale. Higher ER difficulties were significantly associated with elevated depressive symptoms during pregnancy to 14–23 weeks postnatal, independent of confounders. ER difficulties also differed between PeriND symptom trajectories, with higher scores in early and late postnatal-onset groups. These findings highlight ER assessed in the second trimester as a potential vulnerability marker for PeriND, with the DERS-16 offering promise for early risk detection. Targeting ER may provide a promising strategy for mitigating perinatal mental health risks. Weinmar et al. examined the link between emotion regulation and perinatal depression symptoms in a Swedish population-based cohort.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 11","pages":"1352-1362"},"PeriodicalIF":8.7,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s44220-025-00531-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-31DOI: 10.1038/s44220-025-00539-8
This precision medicine trial shows that guanfacine, a selective α2A adrenoreceptor agonist, restores the function of the cognitive control circuit in patients with the cognitive biotype of depression. Circuit engagement was accompanied by improved cognition and high response and remission rates. Thus, targeted treatments show potential to accelerate personalized psychiatric care.
{"title":"Targeting a specific molecular mechanism alleviates the cognitive biotype of depression","authors":"","doi":"10.1038/s44220-025-00539-8","DOIUrl":"10.1038/s44220-025-00539-8","url":null,"abstract":"This precision medicine trial shows that guanfacine, a selective α2A adrenoreceptor agonist, restores the function of the cognitive control circuit in patients with the cognitive biotype of depression. Circuit engagement was accompanied by improved cognition and high response and remission rates. Thus, targeted treatments show potential to accelerate personalized psychiatric care.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 11","pages":"1302-1303"},"PeriodicalIF":8.7,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-30DOI: 10.1038/s44220-025-00528-x
Giulia G. Piazza, Andrea G. Allegrini, Larisa Duffy, Gemma Lewis, Glyn Lewis, Jonathan P. Roiser, Jean-Baptiste Pingault
Depression consists of heterogeneous symptoms that can occur in hundreds of possible combinations. However, intervention studies commonly operationalize depression as a homogeneous condition. Here we adopt a symptom-level approach to test the effects of the selective serotonin reuptake inhibitor sertraline on depression and anxiety symptoms and to test their associations. Using data from the PANDA randomized controlled trial, we use network models to estimate the effects of sertraline at different time points (contemporaneous networks at 2, 6 and 12 weeks) and across time (temporally lagged networks). Results show that sertraline has beneficial effects on core depression and anxiety symptoms as early as after 2 weeks of treatment, counteracted by detrimental effects on somatic symptoms of depression. This intricate pattern of treatment effects is typically masked when measuring depression on a single dimension. Focusing on individual symptoms of depression and anxiety may shed light on the nature, effectiveness and timing of antidepressant action. This research adopts a symptom-level approach to evaluate the effects of sertraline on depression and anxiety using network models from the PANDA trial, revealing early benefits for core symptoms while highlighting adverse impacts on somatic manifestations over time.
{"title":"The effect of sertraline on networks of mood and anxiety symptoms: secondary analysis of the PANDA randomized controlled trial","authors":"Giulia G. Piazza, Andrea G. Allegrini, Larisa Duffy, Gemma Lewis, Glyn Lewis, Jonathan P. Roiser, Jean-Baptiste Pingault","doi":"10.1038/s44220-025-00528-x","DOIUrl":"10.1038/s44220-025-00528-x","url":null,"abstract":"Depression consists of heterogeneous symptoms that can occur in hundreds of possible combinations. However, intervention studies commonly operationalize depression as a homogeneous condition. Here we adopt a symptom-level approach to test the effects of the selective serotonin reuptake inhibitor sertraline on depression and anxiety symptoms and to test their associations. Using data from the PANDA randomized controlled trial, we use network models to estimate the effects of sertraline at different time points (contemporaneous networks at 2, 6 and 12 weeks) and across time (temporally lagged networks). Results show that sertraline has beneficial effects on core depression and anxiety symptoms as early as after 2 weeks of treatment, counteracted by detrimental effects on somatic symptoms of depression. This intricate pattern of treatment effects is typically masked when measuring depression on a single dimension. Focusing on individual symptoms of depression and anxiety may shed light on the nature, effectiveness and timing of antidepressant action. This research adopts a symptom-level approach to evaluate the effects of sertraline on depression and anxiety using network models from the PANDA trial, revealing early benefits for core symptoms while highlighting adverse impacts on somatic manifestations over time.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 11","pages":"1417-1424"},"PeriodicalIF":8.7,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s44220-025-00528-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：